While AI is reshaping frontline healthcare at pace—spotting cancers, triaging patients, and summarising records—its uptake in ...

Novartis has unveiled plans to invest $23bn into its US-based infrastructure over the next five years, allowing it to produce ...

Johnson & Johnson (J&J) has announced that an injectable version of Rybrevant (amivantamab) has been approved by the European ...

Bayer’s Vitrakvi (larotrectinib) has been granted traditional approval by the US Food and Drug Administration (FDA) to treat ...

Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), ...

Discover how generative AI is revolutionising clinical trials, from enhancing patient recruitment to improving data analysis.

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

Sanofi’s tolebrutinib has been shown to delay disability progression in multiple sclerosis (MS) patients, according to phase ...

The ongoing COMPANION-002 trial has been evaluating the candidate, tovecimig (formerly CTX-009), alongside paclitaxel in ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

Johnson & Johnson (J&J) has shared positive results from a phase 3b study of Tremfya (guselkumab) in adults with psoriatic arthritis (PsA). The APEX trial has been comparing the drug against placebo ...